免疫检查点抑制剂在复发或转移性头颈鳞癌的治疗进展

Progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma

以铂类为基础的化疗联合西妥昔单抗是复发或转移性头颈鳞状细胞癌(R/M HNSCC)的标准治疗方式,然而治疗后有易复发、中位生存期短等问题。以PD-1/PDL-1单抗为主的免疫检查点抑制剂(ICIs)开始成为R/M HNSCC新的临床治疗方案,且pembrolizumab和nivolumab都已被FDA批准用于经铂类治疗失败的R/M HNSCC。现就ICIs在R/M HNSCC的临床试验进行系统汇总,并对药物的不良反应及生物标志物进行阐述,为未来在R/M HNSCC中使用ICIs提供理论基础。

Platinum-based chemotherapy combined with cetuximab is the standard treatment for recurrent or metastatic head and neck squamous cell cancer(R/M HNSCC),but facing easy recurrence with a short survival time. Immune checkpoint inhibitors(ICIs),that mainly meant PD-1/PDL-1 monoclonal antibodies,have become a new clinical therapy program for R/M HNSCC,and both pembrolizumab and nivolumab have been approved by the FDA for R/M HNSCC patients with previous platinum-based treatment failure. This review systematically summarizes the clinical trials of ICIs in R/M HNSCC and describes the toxic side effects and biomarkers of the drugs,in order to provide theoretical basis for clinical usage of ICIs in future.